

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,
Petitioner,

v.

RESEARCH CORPORATION TECHNOLOGIES, INC.,
Patent Owner.

Case No. IPR2016-00204
Patent No. RE 38,551

PATENT OWNER'S EXHIBIT LIST

LIST OF EXHIBITS

Exhibit	Description
2001	Richard H. Mattson, <i>Efficacy and Adverse Effects of Established and New Antiepileptic Drugs</i> , 36 (Suppl. 2) <i>Epilepsia</i> S13-S26 (1995).
2002	Richard H. Mattson, <i>Drug Treatment of Uncontrolled Seizures, in Surgical Treatment of Epilepsy</i> 29-35 (William H. Theodore ed., 1992).
2003	FDA Approved Labeling Text dated August 27, 2012 for FELBATOL [®] (felbamate), available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf (last visited Feb. 2, 2016).
2004	Judith D. Conley & Harold Kohn, <i>Functionalized DL-Amino Acid Derivatives. Potent New Agents for the Treatment of Epilepsy</i> , 30 <i>J. Med. Chem.</i> 567-574 (1987).
2005	U.S. Provisional Patent Application No. 60/013,522.
2006	Bialer <i>et al.</i> , <i>Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)</i> , 51 <i>Epilepsy Res.</i> 31-71 (2002).
2007	Jerry March, <i>Advanced Organic Chemistry</i> 94-96 (4th ed. 1992).
2008	Decision Denying Institution of <i>Inter Partes</i> Review, IPR2014-01126, Paper 22.
2009	Curriculum Vitae of Dr. Farrokh Mistree, September 2014.
2010	Marcy Barge & W.T. Ingram, <i>Inverse Limits on [0,1] Using Logistic Bonding Maps</i> , 72 <i>Topology and its Applications</i> 159-72 (1996).
2011	Jack McBryde Jr., <i>Inverse Limits on Arcs Using Certain Logistic Maps as Bonding Maps</i> , Master's Thesis, University of Houston, (1987).
2012	Trial Testimony of Dr. Clayton Heathcock, <i>UCB, Inc., et al., v. Accord Healthcare, Inc., et al.</i> , No. 13-1206-LPS (D. Del., Nov. 9, 2015).


Exhibit	Description
2013	FDA Approved Labeling Text dated July 9, 2015 for VIMPAT [®] (lacosamide), <i>available at</i> http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022253s030,022254s022,022255s016lbl.pdf (last visited Feb. 2, 2016).
2014	Wolfgang Löscher & Dieter Schmidt, <i>Strategies in Antiepileptic Drug Development: Is Rational Drug Design Superior to Random Screening and Structural Variation?</i> , 17 <i>Epilepsy Research</i> 95-134 (1994).
2015	Michael A. Rogawski & Roger J. Porter, <i>Antiepileptic Drugs: Pharmacological Mechanisms and Clinical Efficacy with Consideration of Promising Developmental Stage Compounds</i> , 42(3) <i>Pharmacological Reviews</i> 223-86 (1990).
2016	John M. Pellock, <i>Standard Approach to Antiepileptic Drug Treatment in the United States</i> 35 (Suppl. 4) <i>Epilepsia</i> S11-S18 (1994).
2017	Approval Listing dated December 27, 1994 for lamotrigine, Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book), http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020241&TABLE1=OB_Rx (last visited Feb. 2, 2016).
2018	The Merck Index 77, 290, 404, 407, 408, 508, 640, 670, 733, 915, 998, 999, 1020, 1028, 1207, 1246, 1247, 1251, 1259, 1260, 1330, 1654 (Susan Budavari et al. eds., 12th ed. 1996).
2019	Approval Listing dated August 5, 1996 for fosphenytoin sodium, Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book), http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020450&TABLE1=OB_Rx (last visited Feb. 2, 2016).
2020	FDA Approved Labeling Text dated January 2014 for CEREBYX [®] (fosphenytoin sodium injection) , <i>available at</i> http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020450s023lbl.pdf (last visited Feb. 2, 2016).

Exhibit	Description
2021	ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Beclamide, http://chem.sis.nlm.nih.gov/chemidplus/rn/501-68-8 (last visited Feb. 2, 2016).
2022	ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Phenacemide, http://chem.sis.nlm.nih.gov/chemidplus/rn/63-98-9 (last visited Feb. 2, 2016).
2023	ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Valproic acid, http://chem.sis.nlm.nih.gov/chemidplus/rn/99-66-1 (last visited Feb. 2, 2016).
2024	Portfolio – Mont Alto Capital, http://www.montaltocapital.com/portfolio/ (last visited Feb. 23, 2016).
2025	Trial Transcript, <i>UCB, Inc., et al., v. Accord Healthcare, Inc., et al.</i> , No. 13-1206-LPS (D. Del., Nov. 9-13, 2015). (served, but not filed, March 17, 2016)
2026	PTAB Telephonic Conference Transcript, IPR2016-00204 (March 8, 2016).

Dated: March 17, 2016

COVINGTON & BURLING LLP
 One CityCenter
 850 Tenth Street NW
 Washington, DC 20001
 (202) 662-6000

Respectfully submitted,

By 


Andrea G. Reister
 Registration No.: 36,253
 Jennifer L. Robbins
 Registration No.: 61,163
 Enrique D. Longton
 Registration No.: 47,304
 Attorneys for Patent Owner

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6, I hereby certify that on this 17th day of March 2016, the foregoing **Patent Owner's Exhibit List and Exhibits 2025-2026** were served by electronic mail, by agreement of the parties, on the following counsel of record for petitioner:

Matthew J. Dowd (MatthewDowd@andrewskurth.com)
Justin W. Crotty (JustinCrotty@andrewskurth.com)
Andrews Kurth LLP
1350 I Street, NW, Suite 1100
Washington DC 20005

Dated: March 17, 2016


Andrea G. Reister, Esq.
Registration No. 36,253